Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea.

Piccini JP, Pokorney SD, Anstrom KJ, Oldenburg O, Punjabi NM, Fiuzat M, Tasissa G, Whellan DJ, Lindenfeld J, Benjafield A, Woehrle H, Blase A, O'Connor CM.

Heart Rhythm. 2019 Jan;16(1):91-97. doi: 10.1016/j.hrthm.2018.07.027. Epub 2018 Jul 27.

PMID:
30059750
2.

Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial.

Daubert MA, Whellan DJ, Woehrle H, Tasissa G, Anstrom KJ, Lindenfeld J, Benjafield A, Blase A, Punjabi N, Fiuzat M, Oldenburg O, O'Connor CM.

Am Heart J. 2018 Jul;201:40-48. doi: 10.1016/j.ahj.2018.03.026. Epub 2018 Apr 8.

PMID:
29910054
3.

Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial.

O'Connor CM, Whellan DJ, Fiuzat M, Punjabi NM, Tasissa G, Anstrom KJ, Benjafield AV, Woehrle H, Blase AB, Lindenfeld J, Oldenburg O.

J Am Coll Cardiol. 2017 Mar 28;69(12):1577-1587. doi: 10.1016/j.jacc.2017.01.041. Erratum in: J Am Coll Cardiol. 2017 May 9;69(18):2355.

4.

Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study.

Fiuzat M, Oldenberg O, Whellan DJ, Woehrle H, Punjabi NM, Anstrom KJ, Blase AB, Benjafield AV, Lindenfeld J, O'Connor CM.

Contemp Clin Trials. 2016 Mar;47:158-64. doi: 10.1016/j.cct.2016.01.001. Epub 2016 Jan 19.

PMID:
26806668
5.

The long and winding road to FDA approval of a novel prostate cancer test: our story.

Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J.

Clin Chem. 2013 Jan;59(1):32-4. doi: 10.1373/clinchem.2012.198739. Epub 2012 Nov 28. No abstract available.

PMID:
23193060
6.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.

Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

PMID:
21820580
7.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

8.

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J.

J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17.

PMID:
20850153
9.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

10.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
11.

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I.

J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15. Erratum in: J Urol. 2009 Mar;181(3):1507.

PMID:
18707724
12.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
13.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
14.

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, Groskopf J, Vessella RL.

Clin Chim Acta. 2008 Mar;389(1-2):1-6. Epub 2007 Nov 17. Erratum in: Clin Chim Acta. 2009 Jul;405(1-2):164.

PMID:
18061575
15.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.

Urology. 2007 Mar;69(3):532-5.

PMID:
17382159
16.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.

Clin Chem. 2006 Jun;52(6):1089-95. Epub 2006 Apr 20.

PMID:
16627561
17.

Day to day changes in free and total PSA: significance of biological variation.

Nixon RG, Wener MH, Smith KM, Parson RE, Blase AB, Brawer MK.

Prostate Cancer Prostatic Dis. 1997 Dec;1(2):90-96.

18.

Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.

Letran JL, Blase AB, Loberiza FR, Meyer GE, Ransom SD, Brawer MK.

J Urol. 1998 Aug;160(2):426-9.

PMID:
9679891
19.

Comparison of 3 investigational assays for the free form of prostate specific antigen.

Nixon RG, Meyer GE, Blase AB, Gold MH, Brawer MK.

J Urol. 1998 Aug;160(2):420-5.

PMID:
9679890
20.

How many mistakes, how to find them.

Blase AB.

Clin Chem. 1997 May;43(5):897-902. Review.

PMID:
9166260
21.

Five PSA methods compared by assaying samples with defined PSA ratios.

Blase AB, Sokoloff RL, Smith KM.

Clin Chem. 1997 May;43(5):843-5. No abstract available. Erratum in: Clin Chem 1997 Aug;43(8 Pt 1):1471.

PMID:
9166240

Supplemental Content

Support Center